PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10356984-0	1999	Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects.	Resveratrol	0-11	mitogen-activated protein kinase 3	Homo sapiens	21-25	
10356984-0	1999	Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects.	Resveratrol	0-11	endothelin 1	Homo sapiens	107-119	
10356984-1	1999	In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites.	Resveratrol	56-67	mitogen-activated protein kinase 3	Homo sapiens	99-103	
10356984-1	1999	In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites.	Resveratrol	56-67	mitogen-activated protein kinase 3	Homo sapiens	213-221	
10356984-1	1999	In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites.	Resveratrol	56-67	mitogen-activated protein kinase 8	Homo sapiens	223-228	
10356984-1	1999	In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites.	Resveratrol	56-67	mitogen-activated protein kinase 1	Homo sapiens	233-236	
10356984-1	1999	In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites.	Resveratrol	69-73	mitogen-activated protein kinase 3	Homo sapiens	99-103	
10356984-1	1999	In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites.	Resveratrol	69-73	mitogen-activated protein kinase 3	Homo sapiens	213-221	
10356984-1	1999	In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites.	Resveratrol	69-73	mitogen-activated protein kinase 8	Homo sapiens	223-228	
10356984-1	1999	In porcine coronary arteries, short-term treatment with resveratrol (RSVL) substantially inhibited MAPK activity (IC50 = 37 microM); and immunoblot analyses revealed consistent reduction in the phosphorylation of ERK-1/-2, JNK-1 and p38, at active sites.	Resveratrol	69-73	mitogen-activated protein kinase 1	Homo sapiens	233-236	
10356984-2	1999	Endothelin-1 (ET-1), a primary antecedent in coronary heart diseases, enhanced MAPK activity, phosphorylation and nuclear translocation in a concentration-responsive but RSVL-sensitive manner.	Resveratrol	170-174	endothelin 1	Homo sapiens	0-12	
10356984-4	1999	Likewise, inhibition of MAPK by RSVL was not reversed by the estrogen receptor blockers tamoxifen and ICI-182,780.	Resveratrol	32-36	mitogen-activated protein kinase 3	Homo sapiens	24-28